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ABSTRACT
Allogeneic transplantation offers a potential cure for patients with Philadelphia chromosome–positive acute lym-
phoblastic leukemia (Ph ALL). We performed a retrospective analysis examining pretransplantation and posttrans-
plantation prognostic factors in 90 patients with Ph ALL. The median age of the patients was 33 years, with slightly
more than half of the patients (58%) in clinical remission at the time of transplantation. Overall, patients had a
nonrelapse mortality rate of 30%, a relapse percentage of 34%, and an estimated 5-year disease-free survival rate of
30%. Pretransplantation risk factors for relapse included the expression of the p190 transcript (relative risk [RR] 
5.1; P .037), evidence of morphologic disease at the time of transplantation (RR 3.9; P < .001), and type of donor
(RR  2.5; P  .015), with patients receiving autologous or matched related transplants having the highest risk of
relapse. The detection of minimal residual disease by reverse transcription polymerase chain reaction for bcr-abl
transcripts was a significant posttransplantation risk factor for relapse (RR  4.4; P  .001), with posttransplantation
patients expressing the p190 transcript having the highest risk of relapse (RR  8.7; P  .0001). In addition, patients
with chronic extensive graft-versus-host disease showed a significantly lower risk of relapse (RR  0.33; P  .038).
Thus, these findings indicate that several pretransplantation and posttransplantation risk factors exist for patients
with Ph ALL. Together, these factors can be used to improve our risk stratification of patients with Ph ALL who
undergo transplantation, which will greatly enhance our ability to counsel these patients and potentially lead to the
development of more specific treatment plans for them.
© 2003 American Society for Blood and Marrow Transplantation
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INTRODUCTION
The Philadelphia chromosome (Ph) creates a unique fusion
gene by adjoining the proximal BCR gene to the distal ABL gene
[1]. Approximately 20% of adults with acute lymphoblastic leu-
kemia (ALL) harbor the Ph chromosome and, thus, express the
bcr-abl gene [2-4]. Although several different bcr-abl transcripts
have been described in a variety of different leukemias, the 2
prominent types of bcr-abl transcripts in ALL are the p190 and
p210 transcripts [5]. Patients with Ph ALL have a poor prog-
nosis, with a disease-free survival (DFS) rate between 0 and 20%
after standard chemotherapy [2,6,7]. For patients with a suitable
donor, allogeneic transplantation offers a potential cure and a
DFS between 35% and 75% [2,7-11].
Despite the encouraging results with transplantation, 30%
to 50% of patients with Ph ALL will relapse after transplan-
tation [8,12]. Treatments previously have been limited for pa-
tients who relapse after transplantation [13,14]; however, novel
therapeutic approaches are being developed for these patients.
These treatments include donor lymphocyte infusions, adoptive
immunotherapy, interferon, second transplantations with non-
myeloablative regimens, and small molecular inhibitors [13-17].
These treatments may be most beneﬁcial in patients with low
tumor burden [18]. Thus, the ability to predict which patients
are at high risk of relapse after transplantation and to monitor
patients for the development of early relapse could be of beneﬁt.
Multiple factors, such as conditioning regimen, donor sta-
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tus, phase of disease at time of transplantation, graft-versus-host
disease (GVHD), and detection of minimal residual disease
(MRD) by bcr-abl assays, are associated with posttransplantation
relapse in chronic myeloid leukemia (CML) [19-21]. Similar to
CML, bcr-abl assays can be used to detect MRD in patients with
Ph ALL [22]. Previously, we studied 36 patients with Ph
ALL to examine if the detection of bcr-abl transcripts predicted
relapse after transplantation [12]. In this study, we expand on
this earlier study by examining pretransplantation and posttrans-
plantation bcr-abl status as well as other possible predictors of
relapse in 90 patients with Ph ALL who underwent hemato-
poietic transplantation at our Center.
MATERIALS AND METHODS
Patients
All patients with Ph ALL referred to the Fred Hutchinson
Cancer Research Center (FHCRC) for transplantation were
eligible for study. All patients were enrolled on Institutional
Review Board–approved protocols with informed consent
signed. Marrow and peripheral blood (PB) samples were in-
tended to be collected before etransplantation and at posttrans-
plantation days 21, 56, and 80 and at 6-month intervals there-
after. A total of 90 patients with Ph ALL underwent
transplantation at FHCRC between October 1989 and January
2001. Posttransplantation samples from 36 of these patients
were reported in a previous study [12].
Reverse Transcription Polymerase Chain Reaction
Amplification of bcr-abl Transcripts
RNA isolation and reverse transcription polymerase chain
reaction (RT/PCR) ampliﬁcation were performed on each avail-
able sample as previously described [12]. The expected RT/PCR
ampliﬁcation products for p210 bcr-abl transcripts are 304 base
pair (bp) or 234 bp, depending on the presence or absence of
BCR exon b3. For the p190 bcr-abl transcript, the ampliﬁcation
product is 190 bp. Identiﬁcation of speciﬁc bcr-abl transcript was
based on the size of the RT/PCR product as determined using
electrophoresis on 2% agarose. RNA samples from ALL-1 and
K562 cell lines were used as positive controls for p190 and p210
bcr-abl transcripts, respectively. RT/PCR assays for both ALL-1
and K562 messenger RNA detected the bcr-abl transcripts in
dilution curves as low as 10-5 (1 part positive control in a
background of 100,000 parts normal bone marrow [BM]). RT/
PCR ampliﬁcation of 2-microglobulin was used to test the
quality of each patient’s RNA sample. Any samples without a
positive 2-microglobulin or experiments without ampliﬁcation
of 10-5 positive controls were repeated. All experiments had a
no-template reaction (negative control) to assess for contamina-
tion. A positive RT/PCR for bcr-abl was deﬁned as a positive
signal of the appropriate size, with appropriate negative and
positive controls. Carryover and contamination were reduced
through strict isolation of postampliﬁcation products and ﬁl-
tered pipet tips as previously described [12].
Cytogenetic Analysis
Chromosomes were prepared, and trypsin Giemsa banding
patterns were analyzed from direct, 24-hour, and 48-hour un-
stimulated BM as previously described [12].
Direct Nucleotide Sequencing of PCR Products
Any ambiguous PCR products were veriﬁed by direct nu-
cleotide sequencing using the 3100 Genetic Analyzer (Applied
Biosystems Inc Foster City, CA) as previously described [12].
Transplantation Regimen
Most patients (n  86; 96%) received a conditioning regi-
men with total body irradiation (TBI) between 1200 and 1575
cGy plus cyclophosphamide (Cy) of 120 mg/kg during 2 days.
Within this group of 86 patients, 7 patients also received anti-
thymocyte globulin and 5 patients received VP-16. For the
other 4 patients, 2 patients were conditioned with BCNU, Cy,
and VP-16, 1 with TBI (600 cGy), Cy, and VP-16, and 1 with a
nonmyeloablative regimen of ﬂudarabine and TBI (200 cGy).
Except for the 1 patient who underwent nonmyeloablative
transplantation who received GVHD prophylaxis with cyclo-
sporine and mycophenolate mofetil, all other patients who un-
derwent allogeneic transplantation received GVHD prophylaxis
with methotrexate and cyclosporine as previously described [23].
Definitions of Outcomes and Statistics
Pretransplantation relapse was deﬁned as any patient with
5% blasts in BM or abnormal blasts in PB. All other pretrans-
plantation patients were deﬁned as being in complete remission
(CR). Posttransplantation relapse was deﬁned as a patient with
(1) 5% blasts in the BM, (2) leukemic blasts in the PB, (3)
evidence of the Ph chromosome on cytogenetic examination in
either BM or PB, or (4) extramedullary involvement of leuke-
mia. All other posttransplantation patients were considered to
be in CR. Median follow-up time was calculated as the median
difference between date of last contact and transplantation date.
Nonrelapse mortality (NRM) was deﬁned as death due to any-
thing other than relapse or the treatment of relapse. Acute
GVHD (aGVHD) and chronic GVHD (cGVHD) were deﬁned
as previously described, with cGVHD being divided into limited
or extensive [24,25]. Relapse rates were estimated using cumu-
lative incidence statistics [26]. The probability of survival was
estimated using the Kaplan-Meier method [27]. Survival rates
were compared using the log-rank test. MRD as indicated by
bcr-abl positivity was used as a time-dependent covariate in a Cox
regression model comparing the hazard rates of relapse [28].
Therefore, if a patient had several posttransplantation RT/PCR
measurements for bcr-abl, the patient’s bcr-abl status might
change over time in the analysis. In addition, the time to relapse
data were treated as left-truncated, so that a patient did not enter
the risk set until the ﬁrst RT/PCR was performed. Patients who
were positive for bcr-abl on a sample also showing morphological
or cytogenetic relapse were classiﬁed according to the bcr-abl
status on the previous RT/PCR. We report P values from the
Wald test for effects in the Cox regression models.
RESULTS
Patients and Clinical Outcomes
A total of 90 patients with Ph ALL underwent transplan-
tation at FHCRC between October 1989 and January 2001
(Table 1). The median age of the patients was 33 years (range,
2-56 years), with a median time of follow-up for all 90 patients
of 280 days (range, 4-4004 days). The median follow-up for
surviving patients was 1516 days (range, 29-4004 days). More
Transplant Prognostic Factors in Ph ALL
207BB&MT
than half of the patients (N  52; 58%) were in CR at the time
of transplantation. Twenty-seven of 90 (30%) patients died
without relapse, and 31 of 90 (34%) patients relapsed. The DFS
and overall survival (OS) rates for the 90 patients were similar,
with both approximately 30% at 5 years (Figure 1).
Pretransplantation Predictors of Relapse
Patients in ﬁrst CR or subsequent CR had a better clinical
outcome than those patients in relapse at the time of transplan-
tation (Table 2). In univariate analyses of the 90 patients, donor
type, phase of disease, and year of transplantation had a signif-
icant impact on the relative risk (RR) of relapse (Table 3). In
multivariate analyses, clinical relapse at the time of transplanta-
tion was the strongest predictor of relapse after transplantation
(RR  3.9; P  .001). Donor type (auto/twin/matched related
donor versus mismatched related donor/unrelated) remained
predictive (RR  2.9; P  .005) after controlling for remission
status and year of transplantation. The increased risk of relapse
in patients who have undergone transplantation recently was
probably because of a higher percentage of patients undergoing
transplantation in clinical relapse during this time period (1996
to 2001  68% versus 1989 to 1995  49%; Chi-squared test,
P  .065). Although age did not have an impact on relapse
(Table 3), the age of the patient appeared to inﬂuence survival.
In a multiple Cox regression model accounting for remission
status, patients aged 33 years or older had a higher risk of death
compared with younger patients (RR  1.7; P  .042).
Pretransplantation bcr-abl Expression as a Predictor
of Relapse
We investigated whether bcr-abl status before transplanta-
tion was predictive of relapse. Of the 90 patients, 51 patients had
Table 1. Patient Characteristics and Type of Transplantation
Patients
No. of patients 90
Sex (No., percent male) 52 (58)
Age (median, range in years) 33 (2-56)
Phase of disease (No., percent)
Remission 52 (58)
Relapse 38 (42)




Autologous or syngeneic 8 (9)
Conditioning (No., percent)
>1200 cGY 86 (96)
Chemotherapy only or <1200 cGY 4 (4)
Figure 1. OS and DFS estimates for all patients (n  90). The graph
shows that OS and DFS curves essentially overlap one another, indicat-
ing that most patients who relapse die. In addition, the curves begin to
plateau after 2 years, suggesting that long-term survival is possible.
Table 2. Outcomes for 90 Patients With Ph ALL
Auto/
Twin MRD MMRD URD
Total
(%)
First CR (n  42)
Alive without relapse 2 6 2 13 23 (55)
Relapse 2 5 0 1 8 (19)
NRM 0 4 2 5 11 (26)
Total 4 15 4 19 42 (100)
Subsequent CR (n  10)
Alive without relapse 1 0 0 3 4 (40)
Relapse 0 1 0 2 3 (30)
NRM 0 1 0 2 3 (30)
Total 1 2 0 7 10 (100)
Relapse (n  38)
Alive without relapse 0 1 2 2 5 (13)
Relapse 3 9 4 4 20 (53)
NRM 0 4 4 5 13 (34)
Total 3 14 10 11 38 (100)
All patients (n  90)
Alive without relapse 3 7 4 18 32 (36)
Relapse 5 15 4 7 31 (34)
NRM 0 9 6 12 27 (30)
Total 8 31 14 37 90 (100)
MRD indicates matched related donor; MMRD, mismatched related
donor; URD, unrelated donor; Auto, autologous transplant.
Table 3. Univariate Analyses of Pretransplantation Predictors of Relapse
n
Relapse
n (%) RR 95% CI P*
Age
<33 y 45 15 (33) 1.0
>33 y 45 16 (36) 1.4 0.70-2.9 .33
Donor status
Unrelated 37 7 (19) 1.0
Mismatched related 14 4 (29) 1.7 0.49-5.8 .40
Matched related 31 15 (48) 3.0 1.2-7.5 .015
Auto or syngeneic 8 5 (63) 3.1 0.98-9.7 .055
Transplantation year
1989-1995 49 12 (24) 1.0
1996-2001 41 19 (46) 2.3 1.1-4.7 .032
Phase of disease
Clinical remission 52 11 (21) 1.0
Clinical relapse 38 20 (53) 4.0 1.9-8.4 .0003
MRD
bcr-abl negative 17 2 (12) 1.0
bcr-abl positive 34 15 (44) 4.0 0.92-18 .065
CI indicates conﬁdence interval.
*P calculated using Wald test in Cox regression model.
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a RT/PCR test for bcr-abl expression immediately before trans-
plantation, with the remaining 39 patients refusing the test or
with the test not being ordered on their pretransplantation
evaluation. These 51 patients were not statistically different with
respect to age, gender, donor type, disease phase, conditioning
regimen, or outcomes compared with the 39 patients without a
pretransplantation bcr-abl assay. The majority of the 51 patients
(n  34; 67%) had a positive bcr-abl assay immediately before
transplantation, whereas the other 17 patients showed no evi-
dence of bcr-abl expression using RT/PCR assays. Half (n  17)
of the 34 patients with positive bcr-abl assays were classiﬁed as
being in clinical remission based on morphologic examination of
BM immediately before transplantation. The incidence of re-
lapse for the 17 patients who were bcr-abl–negative before trans-
plantation was 12%, compared with 44% in the 34 patients with
a positive pretransplantation bcr-abl assay. After adjusting for
clinical stage of disease at transplantation, pretransplantation
bcr-abl–positivity conferred a marginally signiﬁcant increased
RR of relapse (RR  3.5; P  .095), suggesting that MRD as
indicated by a positive bcr-abl test may be an independent pre-
transplantation predictor of relapse. Patients in CR without
MRD (as determined using bcr-abl assay) had the highest DFS,
followed by patients in CR with MRD, and then patients in
known clinical relapse (Figure 2).
Posttransplantation Predictors of Relapse
We also examined posttransplantation factors that might
inﬂuence the RR of relapse and OS in patients with Ph ALL.
aGVHD and cGVHD were treated as time-dependent covari-
ates, with cGVHD analyzed in patients who survived to 100 days
after transplantation. In univariate analyses, aGVHD (RR 
0.67; P  .44) was not signiﬁcantly associated with ALL relapse,
whereas extensive cGVHD (RR  0.44; P  .093) was associ-
ated with a marginally signiﬁcant reduction in relapse (Table 4).
After adjusting for pretransplantation risk factors (donor type,
phase of disease at transplantation, and transplantation year),
patients with chronic extensive GVHD showed a statistically
signiﬁcantly lower risk of relapse (RR  0.33; P  .038).
Posttransplantation bcr-abl Expression as a Predictor
of Relapse
Sixty-four patients had at least 1 bcr-abl assay after trans-
plantation and before clinical relapse. Compared with the 26
patients who did not have bcr-abl data after transplantation, these
64 patients were not signiﬁcantly different with respect to gen-
der, age, donor type, or conditioning regimen. Patients without
bcr-abl data after transplantation had a signiﬁcantly higher inci-
dence of NRM compared with those patients with a posttrans-
plantation bcr-abl test (62% versus 17%, Fisher exact test; P 
.001).
Thirty-three of the 64 patients (52%) had positive bcr-abl
assay at some point after transplantation and before clinical
relapse. Of the 33 patients with a bcr-abl positive test after
transplantation, 15 patients (45%) relapsed and 6 died without
relapse. The median time from the ﬁrst positive bcr-abl assay to
relapse was 75 days. Twelve patients with a positive bcr-abl assay
after transplantation remained alive without clinical disease,
with a median follow-up of 2453 days (range, 714-4004 days).
Nine of the 12 patients had only 1 or 2 positive assays and
thereafter had negative test results up through the date of last
contact. Two patients had no more bcr-abl assays after their last
positive test. Only 1 patient remained positive from day 21 to
day 1042 (day of last test). The 12 patients who were positive for
bcr-abl and did not relapse were somewhat more likely to have
had cGVHD compared with the other 45 patients with post-
transplantation bcr-abl data who survived to day 100 (75% versus
47%; P .11). In the 31 patients who were persistently negative
for bcr-abl, 7 patients (23%) relapsed and 5 died without relapse.
The median time from the last negative bcr-abl assay to relapse
was 146 days, and detection of bcr-abl was a signiﬁcant post-
transplantation predictor of clinical relapse (RR  4.4; P 
.001). After adjusting for donor type and disease phase at the
time of transplantation, the presence of MRD posttransplanta-
tion continued to be signiﬁcantly associated with relapse (RR 
3.0; P  .029). The 5-year DFS rate for patients with positive
RT/PCR within 100 days posttransplantation was statistically
lower than those without a positive RT/CR (29% versus 57%; P
 .007) (Figure 3).
Figure 2. DFS by pretransplantation RT/PCR and disease status.
Kaplan-Meier estimates are shown for 3 patient groups: CR and no
evidence of bcr-abl expression (CR, bcr-abl), CR and evidence of bcr-abl
expression (CR, bcr-abl ), and relapse. The difference in DFS between
patients in CR and relapse was statistically signiﬁcant (P  .017). The
differences between the relapse group and each of the CR groups by
bcr-abl expression were not statistically signiﬁcant, but the groups are
shown for descriptive purposes.
Table 4. Univariate Analyses of Posttransplantation Predictors of Relapse
n
Relapse
n (%) RR 95% CI P*
aGVHD
Grade 0-I 18 5 (28) 1.0
Grade II-IV 54 20 (37) 0.67 0.25-1.8 .44
cGVHD
None or limited 31 17 (55) 1.0
Extensive 34 7 (21) 0.45 0.18-1.1 .093
MRD
bcr-abl negative 31 7 (23) 1.0
bcr-abl positive 33 15 (45) 4.4 1.8-11 .0013
*P calculated using Wald test in Cox regression model.
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Type of bcr-abl Transcript as a Predictor of Relapse
The type of bcr-abl transcript detected before transplanta-
tion and after transplantation inﬂuenced the risk of relapse. Of
the 51 patients with a pretransplantation bcr-abl assay, patients
expressing the p190 bcr-abl transcript had a signiﬁcantly in-
creased risk of relapse (RR  5.1; P  .037) compared with
patients without evidence of bcr-abl before transplantation (Ta-
ble 5). Although the p210 bcr-abl transcript did confer a higher
risk of relapse, this risk of relapse was not statistically signiﬁcant
(Table 5). Likewise, expression of the p190 bcr-abl transcript
posttransplantation was associated with a statistically increased
risk of relapse posttransplantation (RR  8.7; P  .001) com-
pared with those without evidence of the bcr-abl expression
(Table 5). Again, the magnitude of the RR for the p210 bcr-abl
expression was not as great and did not reach statistical signif-
icance (Table 5).
DISCUSSION
We investigated possible pretransplantation and posttrans-
plantation risk factors for relapse in 90 patients with Ph ALL
who underwent transplantation at a single institution between
1989 and 2001. Overall, the NRM incidence was 30%, and 34%
of patients relapsed. The overall DFS rate at 5 years was 30%
(Figure 1). Pretransplantation risk factors for relapse included
the following: (1) type of donor (patients receiving an autolo-
gous and/or matched related donor had the highest risk of
relapse); (2) evidence of clinical disease at the time of transplan-
tation; and (3) expression of bcr-abl, particularly the p190 tran-
script. The best pretransplantation prognosis was found in pa-
tients without evidence of morphological or molecular disease.
Patients with evidence of molecular disease but without mor-
phological disease had an intermediate prognosis, whereas those
patients with evidence of morphological disease had the worst
prognosis (Figure 2). Evidence of MRD, especially with the
expression of the p190 transcript, and an absence of cGVHD
were signiﬁcant posttransplantation risk factors for relapse.
In our study, 38 allogeneic patients underwent transplanta-
tion in ﬁrst CR (Table 2), with a median follow-up of 482 days
(range, 13-3822 days). Twenty-one of these patients (58%)
remained alive without relapse. Our results in patients with Ph
ALL who underwent transplantation in ﬁrst CR are similar to
previously reported studies. For example, Synder et al. [11]
examined 23 patients with Ph  ALL (median age, 25 years)
who underwent transplantation in ﬁrst CR with matched related
donors. Synder et al. reported that 14 of the 23 patients (61%)
were alive without disease a median of 34 months after trans-
plantation. We were able to further risk stratify our patients in
CR by evidence of MRD. Those patients in CR without evi-
dence of pretransplantation MRD had the lowest incidence of
relapse (12%) and the highest DFS rate (Figure 2). Transplan-
tation studies in ALL patients without a Ph chromosomal ab-
normality also have found that pretransplantation MRD status
inﬂuences relapse risk [29-31]. These results raise the question
of whether pretransplantation patients with MRD should re-
ceive additional treatment before transplantation.
The transplantation results for patients with Ph ALL in
CR are in stark contrast to the transplantation results for pa-
tients with evidence of morphological disease at the time of
transplantation. In our study, most patients who were not in CR
at the time of transplantation either relapsed (17 of 35, 49%) or
died of other causes (13 of 35, 37%). Only 5 of 35 patients (14%)
remained alive without evidence of disease. Together, the re-
sults from this study add to the growing body of evidence that
disease burden at the time of transplantation is a signiﬁcant
predictor of relapse after transplantation in patients with ALL
and that transplantation in ﬁrst CR appears to be the preferred
treatment option for patients with Ph ALL.
Previous studies have shown that the detection of MRD
after transplantation is highly predictive of relapse [12,19,32].
This study conﬁrms our previous results, reiterating the impor-
tance of MRDmonitoring after transplantation. In our study, 12
of the 33 (36%) patients who had expression of the bcr-abl
transcript after transplantation remained free of clinical disease
at the time of this report. Nine of these 12 patients had only 1
or 2 positive tests and then became negative for the bcr-abl
transcript up through the date of last contact. Two patients had
no additional tests. Only 1 patient had evidence of long-term,
persistent bcr-abl transcript at the time of last contact. The 12
Table 5. Relapse Risk by bcr-abl Type
n
Relapse,
n (%) RR 95% CI P*
Before transplantation
None 17 2 (12) 1.0
p190 19 9 (47) 5.1 1.1-24 .037
p210 8 3 (38) 2.9 0.48-17 .25
p190 and p210 7 3 (43) 3.3 0.55-20 .19
After transplantation
None 31 7 (23) 1.0
p190 14 7 (50) 8.7 3.0-25 .0001
p210 12 4 (33) 2.2 0.65-7.7 .20
p190 and p210 7 4 (57) 5.0 1.5-17 .010
*P calculated using Wald test in Cox regression model.
Figure 3. DFS by RT/PCR from 100 days posttransplantation, stratiﬁed
by evidence of bcr-abl expression. Risk stratiﬁcation by expression of
bcr-abl within the ﬁrst 100 days posttransplantation shows a relationship
between MRD and DFS (P  .007). Kaplan-Meier estimates are shown
for 2 patient groups: no evidence of bcr-abl expression (bcr-abl ) and
evidence of bcr-abl expression (bcr-abl ) within the ﬁrst 100 days
posttransplantation.
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patients expressing bcr-abl transcripts without relapse were more
likely to have had cGVHD compared with the other patients
with posttransplantation bcr-abl data (75% versus 47%; P .11),
suggesting that the immune system may be playing a role in
preventing relapse in patients with Ph ALL with MRD. In-
deed, cGVHD was associated with a lower risk of relapse in
multivariate analyses (RR  0.44; P  .038). Quantitative RT/
PCR, which can provide a determination of the level of bcr-abl
expression, may be a more accurate method than qualitative
RT/PCR to assess the burden of disease and risk of relapse.
Studies have already shown that the posttransplantation burden
of disease, as measured by quantitative RT/PCR for bcr-abl, is
highly predictive of relapse in patients with CML after trans-
plantation [33].
Seven of 31 patients (23%) relapsed without having a pre-
viously positive RT/PCR for bcr-abl. Although attempts were
made to screen these patients at days 21, 56, and 80 and at
6-month intervals, some patients missed blood draws because of
various reasons. Patients with negative bcr-abl tests relapsed a
median of 146 days after their last negative test, whereas those
patients with a positive bcr-abl assay relapsed a median of 75 days
after their ﬁrst positive test. This suggests that we may have
been able to identify additional patients before clinical relapse if
we had screened them at more frequent intervals.
Previously, we found that posttransplantation expression of
the p190 transcript carried a higher RR of relapse than expres-
sion of the p210 [12]. Recently, Kroger et al. [34] were unable to
demonstrate signiﬁcant clinical differences when stratifying 19
patients according to type of transcript expressed before trans-
plantation. In the current analysis, we found that expression of
p190 in both the pretransplantation and posttransplantation
setting was associated with a statistically signiﬁcantly higher risk
of relapse than no expression, whereas the expression of p210
did not confer a signiﬁcantly higher risk. Small sample size could
account for some of the clinical differences between p190 and
p210, but several lines of research predict that clinical outcomes
might differ depending on the type of transcript expressed. In
vitro assays, including experiments in immature lymphoid cells,
have shown that the p190 protein has an increased tyrosine
kinase activity compared with the p210 protein [35,36]. In mu-
rine models, the p190 also was found to cause a more aggressive
form of leukemia [37,38]. Thus, the biology of the 2 transcripts
would suggest that p190 would confer a higher rate of therapy
resistance and a worse prognosis. Our ﬁndings, combined with
the biology data, indicate that differential treatment strategies
may be necessary for patients expressing p190 versus p210.
In summary, multiple pretransplantation and posttransplan-
tation risk factors are available to help risk stratify patients with
Ph ALL undergoing transplantation. The burden of disease at
the time of transplantation and detection of MRD after trans-
plantation are predictive of relapse [29-31]. These data suggest
a future where patients are risk stratiﬁed before transplantation,
and the intensity of conditioning and immunosuppression are
tailored to the patient based on pretransplantation risk factors.
“Low-risk” patients (no evidence of MRD) may be eligible for
less intense conditioning regimens, such as nonmyeloablative
transplantation, whereas “high-risk” patients (MRD or overt
clinical disease) would be eligible for more aggressive immuno-
suppression tapers or even posttransplantation consolidation
with novel treatment approaches, including small molecular
inhibitors aimed at blocking bcr-abl function, such as STI-571
(Gleevec, Novartis, East Hanover, NJ). In addition, our results
reiterate the need to better deﬁne predictors of relapse and to
develop targeted treatment approaches. However, many of these
posttransplantation interventions probably will require a more
precise understanding of the biological (eg, p190 versus 210)
mechanisms that determine relapse.
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